About Eidos Therapeutics
Eidos Therapeutics is a company based in Palo Alto (United States) founded in 2016 by Isabella Graef, Neil Kumar, and Mamoun Alhamadsheh was acquired by BridgeBio in October 2020.. Eidos Therapeutics has raised $64 million across 1 funding round from investors including BridgeBio, Janus Henderson Investors and RA Capital. Eidos Therapeutics offers products and services including Attruby and Nulibry. Eidos Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Palo Alto, United States
- Founders Isabella Graef, Neil Kumar, Mamoun Alhamadsheh
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bridgebio Pharma, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eidos Therapeutics
Eidos Therapeutics offers a comprehensive portfolio of products and services, including Attruby and Nulibry. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Approved drug for treating specific genetic diseases effectively.
Medicine targeting genetic conditions to improve patient outcomes.
Unlock access to complete
Unlock access to complete
Funding Insights of Eidos Therapeutics
Eidos Therapeutics has successfully raised a total of $64M through 1 strategic funding round. The most recent funding activity was a Series B round of $64 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $64.0M
-
First Round
First Round
(05 Apr 2018)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2018 | Amount | Series B - Eidos Therapeutics | Valuation | RA Capital Management , BridgeBio |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eidos Therapeutics
Eidos Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include BridgeBio, Janus Henderson Investors and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eidos Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eidos Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eidos Therapeutics Comparisons
Competitors of Eidos Therapeutics
Eidos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for rare and orphan diseases
|
|
| domain | founded_year | HQ Location |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eidos Therapeutics
Frequently Asked Questions about Eidos Therapeutics
When was Eidos Therapeutics founded?
Eidos Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Eidos Therapeutics located?
Eidos Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Who is the current CEO of Eidos Therapeutics?
Neil Kumar is the current CEO of Eidos Therapeutics. They have also founded this company.
Is Eidos Therapeutics a funded company?
Eidos Therapeutics is a funded company, having raised a total of $64M across 1 funding round to date. The company's 1st funding round was a Series B of $64M, raised on Apr 05, 2018.
What does Eidos Therapeutics do?
Eidos Therapeutics was founded in 2016 in Palo Alto, United States, as a biotechnology firm focused on rare diseases. Small-molecule therapies are developed to address transthyretin (TTR) amyloidosis, with the lead candidate AG10 designed to stabilize TTR proteins and inhibit amyloid formation. Both hereditary and wild-type forms of the disease are targeted through these operations, which emphasize clinical advancement in the therapeutic sector.
Who are the top competitors of Eidos Therapeutics?
Eidos Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Eidos Therapeutics offer?
Eidos Therapeutics offers Attruby and Nulibry.
Who are Eidos Therapeutics's investors?
Eidos Therapeutics has 8 investors. Key investors include BridgeBio, Janus Henderson Investors, RA Capital, Perceptive Advisors, and Viking Global Investors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.